Bayer Aktiengesellschaft (ETR:BAYN)
Germany · Delayed Price · Currency is EUR | Market Cap | 44.77B +114.8% |
| Revenue (ttm) | 45.87B -1.9% |
| Net Income | -198.00M |
| EPS | -0.20 |
| Shares Out | 982.42M |
| PE Ratio | n/a |
| Forward PE | 9.93 |
| Dividend | 0.11 (0.24%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 1,427,194 |
| Average Volume | 3,620,201 |
| Open | 45.18 |
| Previous Close | 45.58 |
| Day's Range | 44.15 - 45.29 |
| 52-Week Range | 18.38 - 49.78 |
| Beta | 0.97 |
| RSI | 49.87 |
| Earnings Date | Mar 4, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial StatementsNews
Bayer proposes $7.25 billion Roundup settlement as Supreme Court case looms
A new $7.25 billion settlement between Bayer and a group of cancer patients could wrap up a huge wave of lawsuits against the company over allegations that it didn't warn consumers about cancer risks ...
Biodexa Licenses Phase 1-Ready Drug Candidate From Otsuka For Rare Stomach Cancer
Zinger Key Point: MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical-stage bi...
Bayer: glyphosate shortages not expected outside the US after executive order
The U.S. President's executive order invoking the Defense Production Act to ensure U.S. supply of glyphosate underscores U.S. farmers' needs to have access to the herbicide, Bayer said on Thursday, ad...
Trump Invokes Defense Act For Monsanto Chemicals: Bayer, Agribusiness ETFs In Focus On New Critical Mineral Status For Phosphorus
In a major move to solidify the America First industrial strategy, President Donald Trump signed an executive order on Feb. 18, mobilizing the Defense Production Act (DPA) to secure the domestic suppl...
Explainer: Will Bayer's proposed $7.25 billion Roundup deal bring legal closure?
Bayer's Monsanto unit has proposed a $7.25 billion nationwide class settlement to resolve both current and future lawsuits alleging that its Roundup weedkiller caused cancer, billing it as a long-awai...
Bayer reaches $7.25 billion settlement over claims that Roundup caused cancer
The settlement comes as the Supreme Court prepares to hear arguments that the EPA's approval of Roundup without a cancer warning should invalidate claims.
Bayer (BAYRY) Agrees to $7.25 Billion Settlement Over Roundup Lawsuits
Bayer (BAYRY) Agrees to $7.25 Billion Settlement Over Roundup Lawsuits
Bayer (BAYRY) Faces Investor Skepticism Over $7.25 Billion Roundup Settlement
Bayer (BAYRY) Faces Investor Skepticism Over $7.25 Billion Roundup Settlement
Bayer stumbles as investors question plan to settle Roundup litigation
First Look: Nvidia-Meta chip pact, Bayer deal, WBD talks
First Look: Nvidia-Meta chip pact, Bayer deal, WBD talks
Bayer Expands Litigation Liability With New $7.25B Roundup Proposal
Bayer proposes a $7.25 billion settlement to resolve Roundup lawsuits over non-Hodgkin lymphoma, expanding its legal liability.
Bayer retreats as investors sour on deal to settle Roundup litigation
Bayer's shares slumped as much as 9.2% on Wednesday, wiping out the previous day's gains, as investors questioned whether a proposed $7.25 billion settlement of cancer lawsuits over its Roundup weedki...
German Pharma Giant Bayer Proposes $7.25 Billion Settlement Over Monsanto's Roundup Cancer Claims In US
Bayer AG (OTC: BAYRY) on Tuesday proposed a $7.25 billion settlement to resolve thousands of U.S. lawsuits claiming that its weedkiller Roundup causes cancer. The product was originally made by Monsa...
Bayer shares make this surprising move after $7.25 billion Roundup settlement accord
Bayer stock slumped on Wednesday as the German giant set a preliminary accord to cap litigation over its weedkiller Roundup.
Bayer falls 7% after proposing $7.25 billion settlement in Roundup case; European markets open higher
European stocks opened higher on Wednesday as investors monitor global market developments.
Bayer stock gains on Roundup settlement
Bayer has agreed to pay a $7.25 billion settlement to resolve lawsuits around cancer allegedly caused by its Roundup weedkiller. The settlement - which still needs to be approved by a U.S. court - wou...
Bayer agrees to $7.25bn proposed settlement over Roundup weedkiller lawsuits
Thousands of lawsuits accuse the agrochemical maker of failing to warn people that its weedkiller could cause cancer Agrochemical maker Bayer and attorneys for cancer patients announced a proposed $7....
Bayer agrees to US$7.25 billion proposed settlement over thousands of Roundup cancer lawsuits
Agrochemical maker Bayer and attorneys for cancer patients announced a proposed $7.25 billion settlement Tuesday to resolve thousands of U.S. lawsuits alleging the company failed to warn people that i...
Bayer offers $7.25bn to settle weedkiller cancer claims
The company has faced years of legal battles over Roundup, a weedkiller made by Monsanto.
Bayer Proposes New $7 Billion Plan to Settle Roundup Litigation
Company says settlement would address bulk of outstanding cases; the Supreme Court has agreed to hear Bayer's appeal to neutralize cancer claims.
Bayer CEO says Roundup settlement is important addition to Supreme Court case
Bayer's U.S. class settlement aimed at resolving current and future claims that Roundup weedkiller caused non‑Hodgkin lymphoma is an important addition to its Supreme Court case, Bayer CEO Bill Anders...
Bayer (BAYRY) Plans $10.5 Billion Settlement for Roundup Lawsuits
Bayer (BAYRY) Plans $10.5 Billion Settlement for Roundup Lawsuits
Bayer: Monsanto Announces Roundup Class Settlement Agreement to Resolve Current and Future Claims
Class settlement and the U.S. Supreme Court case are independently necessary and mutually reinforcing elements in multi-pronged strategy to significantly contain the litigation Funding of the clas...